BioCentury
ARTICLE | Finance

Ebb & Flow

April 18, 2005 7:00 AM UTC

As the sign says, "objects in the rear view mirror are closer than they appear."

On the heels of last week's positive Phase III data for Avastin as first-line therapy for metastatic breast cancer, and positive earnings, Genentech (DNA) added $12.9 billion in market cap and now sits at $76 billion. ...